CymaBay Therapeutics Inc CBAY
Find similar stocks with Morningstar Investor.
Morningstar analysts do not currently cover CBAY, but with our powerful screener, you can find stocks in the same sector, industry, or style and filter on our unbiased ratings and valuation metrics.
News
-
Trending: Gilead Sciences to buy CymaBay for $4.3 Billion
-
CymaBay's stock surges as Gilead reaches $4.3 billion deal for liver-drug developer
-
Gilead Sciences to Buy CymaBay Therapeutics for $4.3 Billion
-
CymaBay Shares Rise 7% After Revised Breakthrough Therapy Designation
-
CymaBay Therapeutics stock jumps as rare liver disease treatment shows positive results
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 111.01
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 101
- Website
- https://www.cymabay.com
Comparables
Valuation
|
Metric
|
CBAY
|
ISEE
|
DYN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 12.65 | 11.49 | 6.21 |
Price/Sales | 111.01 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
CBAY
ISEE
DYN
Financial Strength
|
Metric
|
CBAY
|
ISEE
|
DYN
|
|---|---|---|---|
Quick Ratio | 10.70 | 15.24 | 20.28 |
Current Ratio | 10.96 | 15.53 | 21.83 |
Interest Coverage | −5.27 | — | — |
Quick Ratio
CBAY
ISEE
DYN
Profitability
|
Metric
|
CBAY
|
ISEE
|
DYN
|
|---|---|---|---|
Return on Assets (Normalized) | −30.06% | −42.04% | −77.53% |
Return on Equity (Normalized) | −51.97% | −50.62% | −94.92% |
Return on Invested Capital (Normalized) | −30.87% | −46.07% | −88.19% |
Return on Assets
CBAY
ISEE
DYN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Lxhjzjpdd | Fxrgn | $624.9 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jqpsnbkg | Pshjl | $121.4 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dpdqldrrk | Dxqbqvc | $112.8 Bil | |||
| Moderna Inc
MRNA
| Xnvfpnwyy | Kvcvb | $44.4 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Hnmwbsnl | Yxtrjn | $31.5 Bil | |||
| argenx SE ADR
ARGX
| Mrzvhjs | Kqp | $25.9 Bil | |||
| BioNTech SE ADR
BNTX
| Mcqvsjjxk | Hbwzc | $19.2 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Khtbmcqz | Xsdyvwk | $15.4 Bil | |||
| United Therapeutics Corp
UTHR
| Vhmcvrmsg | Cfxy | $13.8 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Khwtmklghw | Rrmxn | $11.7 Bil |